CDKN2A and neoplasm: Distinct risk factors have been associated with the initiation, progression, advancement, and drug resistance in PanCa, including age, sex, pathological staging, tumor microenvironment, epigenetic alterations, immune landscape, various signaling pathways, and single or multiple genetic aberrations in KRAS, T53, SMAD4, and cyclin-dependent kinase inhibitor 2A (CDKN2A) [5,6].